Aliskiren the first renin inhibitor for clinical treatment

Aliskiren the first renin inhibitor for clinical treatment

ID:40047923

大小:669.97 KB

页数:12页

时间:2019-07-18

Aliskiren the first renin inhibitor for clinical treatment_第1页
Aliskiren the first renin inhibitor for clinical treatment_第2页
Aliskiren the first renin inhibitor for clinical treatment_第3页
Aliskiren the first renin inhibitor for clinical treatment_第4页
Aliskiren the first renin inhibitor for clinical treatment_第5页
资源描述:

《Aliskiren the first renin inhibitor for clinical treatment》由会员上传分享,免费在线阅读,更多相关内容在学术论文-天天文库

1、REVIEWSCasehisToryAliskiren:thefirstrenininhibitorforclinicaltreatmentChrisJensen,PeterHeroldandHansRudolfBrunnerAbstract

2、Thefirstevidenceoftheexistenceofreninwaspresentedover100yearsago.However,theimportanceofreninandtherenin–angiotensinsysteminthepathogenesisofcardiovas

3、culardiseasewasonlyfullyrealizedinthe1970s.Itwasanother20yearsbeforethefirstinhibitorsofreninwereavailableforclinicalresearch.Here,wedescribethediscoveryanddevelopmentofaliskiren,anorallyactiverenininhibitor,whichbecamethefirstdruginitsclasstoreceiveregulatoryapproval.In2

4、007,itwasapprovedforthetreatmentofhypertensionbytheUSFoodandDrugAdministrationandtheEuropeanMedicinesAgency.Aliskirenalmostneverwas.FollowingthemergerofTherenin–angiotensinsystemindiseaseHypertrophyCiba–GeigywithSandoztoformNovartisin1996,TheRAScascadestartswithangiotensi

5、nogen,aproteinAnincreaseinventricularmass,whichistypicallycharacterizedandthelaunchoftheantihypertensivedrugvalsartanthatissecretedbytheliver(FIG. 2).Fromthissubstrate,thebyanincreasedcardiac(Diovan;Novartis)in1997,thefateoftheinvestiga-decapeptideangiotensinIisthencleave

6、dbytheenzymemyocytesizeinconjunctiontionalrenininhibitoraliskirenseemedtobeaforgottenrenin,whichisproducedinthekidney(theactivityofwithcardiacfibrosis.backshelfofaresearchlaboratory.However,asmallreninintheplasmaisreferredtoasplasmareninactivityFibrosisgroupofformerCiba–G

7、eigyemployeesconvincedthe(PRA)).AngiotensinIisthenfurthertransformedbytheTheformationofexcessnewmanagementofNovartistoout-licensealiskirentoangiotensin-convertingenzyme(ACE)toproducetheconnectivetissue.Speedel,astart-upbiopharmaceuticalcompanyestab-octapeptideangiotensinI

8、I,whichbindstoangiotensinlishedin1999,tokeepaliskireninclinicaldevelopmentIIsubtype1receptors(ATreceptors).Thisleadsto1(FIG. 1).anarrowingofbloodvesselsandanincreaseinbloodThediscoveryofrenin1byTigerstedtandBergmanpressure(BP),changesinrenalglomerularandtubularhaditselfre

9、mainedunnoticedformorethan40years,function,inflammationandfibrosisinthekidney,aswellpartlybecaus

当前文档最多预览五页,下载文档查看全文

此文档下载收益归作者所有

当前文档最多预览五页,下载文档查看全文
温馨提示:
1. 部分包含数学公式或PPT动画的文件,查看预览时可能会显示错乱或异常,文件下载后无此问题,请放心下载。
2. 本文档由用户上传,版权归属用户,天天文库负责整理代发布。如果您对本文档版权有争议请及时联系客服。
3. 下载前请仔细阅读文档内容,确认文档内容符合您的需求后进行下载,若出现内容与标题不符可向本站投诉处理。
4. 下载文档时可能由于网络波动等原因无法下载或下载错误,付费完成后未能成功下载的用户请联系客服处理。